FDA Guidance Documents: Reading Them Is Easy, Applying Them Is the Challenge

FDA guidance documents are widely accessible today but reading a one and applying it correctly are two different things. A regulatory professional may understand what a document says, but the real challenge begins when that information has to be applied to a specific product, process, or submission.

FDA regulations set legally enforceable requirements. FDA guidance documents describe the Agency’s current thinking and make recommendations.

Under FDA’s Good Guidance Practices (21 CFR 10.115), guidance documents generally do not establish legally enforceable rights or responsibilities. In guidance, the word “should” means something is suggested or recommended, not required. An Alternative approach is acceptable if it satisfies the applicable statutes and regulations, and FDA invites applicants to discuss alternatives with the Agency.

That distinction matters. Reading a guidance document is only the starting point. You still have to work out what is required, what is recommended, and how each applies to your product or submission.

This is where the difference between reading and applying regulatory information begins.

A practical way to understand the process is through five stages: Identify, Understand, Assess, Implement and Verify

1. Identify the regulations, guidance documents, and submission requirements relevant to your application.
2. Understand what they require or recommend.
3. Assess whether and how they apply to your product and submission.
4. Implement them through the right documentation and submission activities.
5. Verify that each applicable requirement and recommendation has been addressed.

These five stages are not an official FDA framework but a practical way of understanding how regulatory information moves from something we read to something we apply.

FDA’s Good ANDA Submission Practices Guidance, published in January 2022, lists recurring deficiencies in ANDA and how to avoid them. It also reminds applicants that submitting a complete, high-quality application is their own responsibility.

Take the commercial manufacturing process. This is a section the applicant owns entirely. FDA expects applicants to provide details of the commercial process, and the information supporting it, in Modules 3.2.P.2, 3.2.P.3, and 3.2.R. FDA notes that applicants often submit information that is inconsistent, inaccurate, or incomplete, and that this has led to FDA refusing to approve ANDAs.

Among its recommendations, the guidance says applicants should:

• Give set points and ranges for commercial-scale process parameters, stated as actual values. “To Be Determined” should not be used, and ranges should not be open-ended.
• Identify and justify any equipment differences between exhibit and commercial batches in Module 3.2.P.3.
• Present hold times and hold conditions for intermediates and bulk drug product in a table in Module 3.2.P.3.3.
• Make sure the commercial batch formula in 3.2.P.3.2 matches the unit dose composition in 3.2.P.1, with any overage or overfill clearly justified.

Reading this tells you that commercial process details matter. Applying it means opening your own draft and checking:

• Does every process parameter have a defined set point and range?
• Is the hold-time table complete?
• Does the batch formula match the unit composition on 3.2.P.1?
• Is every equipment difference explained?

If something is missing, the team needs to find and fix the gap before submission, not after FDA raise it.

In simple terms, reading creates awareness; application requires action.

Once the relevant guidance is identified and understood, the next risk is overlooking items during submission preparation.

A Structured checklists helps teams organize requirements, documentation, responsibilities, and open items. Instead of relying only on memory, a regulatory professional can review each applicable item and mark it complete, under review, or pending . In the example above, a checklist is how the Verify stage actually gets done.

A checklist does not replace regulatory knowledge or professional judgment. The regulatory professional still decides which recommendations apply to the product and how to address them.  The checklist supports the process; the interpretation comes from the person using it.

Regulatory work does not end when guidance has been read. The real work is to identify what’s relevant, understand it, assess whether it applies, implement it and verify it.

FDA’s Good ANDA Submission Practices guidance shows how incomplete or inconsistent information led to recurring deficiencies.  Reading guidelines builds knowledge. Applying it turns that knowledge into regulatory action.